Nonmalignant Hematology

antithrombotic treatment in BCR/ABL negative myeloproliferative neoplasms.- Bleeding and thrombosis in a cancer patient.- Management of surgical patient with thrombotic and bleeding diathesis.- Part 3. Thrombosis and Therapeutics.- Prevention and treatment of arterial thromboembolism.- mes New Roman","serif"">Prevention of venous thromboembolism.- Diagnostic, prognostic and therapeutic challenges in venous thromboembolisim.- Complications of venous thromboembolic disease.- Hereditary thrombophilias: Pathophysiology, timing of testing and familiar testing.- Anti-phospholipid antibodies and syndrome: Complexities in diagnosis and management.- Unidentifiable thrombophilias.- Anticoagulation drugs: Indications, therapeutic monitoring and antidotes.- Heparin induced thrombocytopenia: Diagnosis and management.- Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.- Surgical treatment of thromboembolic disease.- Part 4. Immune System and Related Disorders.- Nonmalignant leukocyte disorders.- Primary immunodeficiency disorders: Diagnosis and management.- Disorders of phagocytic function: Diagnosis and treatment.- Inherited bone marrow failure syndromes.- Hemophagocytic lymphohistiocytosis: Diagnosis and management challenges.- Lysosomal storage disorders: Hematology perspective.- Cryoglobulins and cryoglobulinemia.- Part 5. Hemostasis and Thrombosis in Pregnancy, Newborn and Elderly.- Reproductive issues in women with bleeding and thrombotic disorders.- Pregnancy in subjects with hemoglobinopathies: Precautions and management.- Neonatal thrombosis and coagulopathies.- Bleeding and thrombosis in elderly.- Part 6. Transfusion Medicine.- Transfusion support: Indications, efficacy and complications.- Human blood antigens and antibodies: Diagnostic and therapeutic implications.- Therapeutic apheresis in hematologic disorders: When and Why?

Hematology/Oncology and Transfusion Medicine at Brigham and Women's Hospital, Boston. Dr Connors cares for patients with inherited and acquired thrombotic and coagulation disorders. As Medical Director of the Brigham and Women's Hospital and Dana Farber Cancer Institute Anticoagulation Management Service, Dr Connors oversees anticoagulation practices in outpatient clinical settings. She is also the Medical Director of the Hemostatic Antithrombotic Stewardship program, a multi-disciplinary care delivery program, to ensure judicious and optimal use of anticoagulants and clotting factors across all BWH inpatient services. She has participated in a variety of types of clinical trials focusing on anticoagulation including investigator initiated, served on scientific advisory boards for a number of companies, teaches extensively at many levels including peers in CME courses as well as fellows and residents, and has written numerous reviews and chapters in the area of thrombosis-hemostasis.

Margaret Ragni is a Professor of Medicine and Clinical Translational Science at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. She received her MD from the University of Pittsburgh School of Medicine and a Master of Public Health from the University of Pittsburgh School of Public Health. She completed her residency and fellowship in hematology/oncology at the University of Pittsburgh Medical Center in Pittsburgh, where she joined the faculty in 1983. Dr. Ragni's research interests are in congenital and acquired disorders of hemostasis and thrombosis, and, in, particular in novel therapeutics for patients with hemophilia with and without inhibitors. She serves on the Medical and Scientific Advisory Committee of the National Hemophilia Foundation (NHF), the FDA Blood Products Advisory Committee, the Scientific Committee on Hemostasis of the American Society of Hematology, and on the Medical Advisory Board for the Foundation for Women and Girls with Blood Disorders (FWGBD). She also served as Co-Chair for the 2014 ASH Annual Meeting; as Co-Chair of the Research Committee of the Hemostasis & Thrombosis Research Society, and is a member of the Research Committee of the American Thrombosis & Hemostasis Network. She is past member of the Hemostasis Thrombosis Study Section of the NHLBI, and Co-Chair of the Bleeding Disorders Subcommittee of the NHLBI State of the Science Symposium. She serves on Scientific Advisory Boards for Alnylam, Baxalta, Biogen, and Biomarin. She has conducted numerous clinical trials, observational studies, retrospective data base analyses, cost-effectiveness analyses, and investigator-initiated new drug trials in hemophilia and von Willebrand disease. She is the medical director of the Hemophilia Center of Western PA, providing care for patients with bleeding and clotting disorders, teach and mentor medical students, residents, fellows, and young faculty.